AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9793313
Drug: Budesonide 0.8
RxNorm normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 0.8 mg/day
Trial: 9793313
Drug: Budesonide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 1.2 mg/day
Trial: 9793313
Drug: Budesonide 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 2.4 mg/day
Trial: 9793313
Drug: Budesonide 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3.2 mg/day
Trial: 2777592
Drug: Betadine‐R solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betadine‐R solution
Trial: 1206393
Drug: L-tryptophan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (1.5 g or 8 g daily for 30 days)
Trial: 1206393
Drug: Placebo (30-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30-day period after treatment)
Trial: 27890885
Drug: Administration Timing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration Timing Simplification Protocol (ATSP)
Trial: 23263204
Drug: Inhalation anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anaesthesia with fentanyl (Group I)
Trial: 23263204
Drug: Inhalation anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anaesthesia with remifentanil (Group II)
Trial: 23263204
Drug: Intravenous anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anaesthesia (TIVA) with propofol and remifentanil (Group III)
Trial: 19243712
Drug: Extended-release niacin/laropiprant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin/laropiprant (ERN/LRPT) combination
Trial: 16677158
Drug: Pantoprazole infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole infusion (80 mg intravenous bolus followed by an infusion at a rate of 8 mg per hour for 72 hours)
Trial: 16677158
Drug: Pantoprazole infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole infusion
Trial: 10341332
Drug: HGV antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGV antibodies detection by serological assay
Trial: 7574743
Drug: HAI chemotherapy
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI chemotherapy with 5-FU 500 mg/day for 6 weeks
Trial: 7574743
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no regional chemotherapy)
Trial: 1973865
Drug: Astemizole 10-mg
RxNorm normalized name: astemizole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole 10-mg tablets
Trial: 6157338
Drug: Antihistamine-decongestant combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine-decongestant combination (azatadine maleate and pseudoephedrine sulfate)
Trial: 30685679
Drug: SurVeil drug-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SurVeil drug-coated balloon (DCB)
Trial: 30685679
Drug: IN.PACT Admiral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN.PACT Admiral drug-coated balloon (DCB)
Trial: 21399488
Drug: Epirubicin, cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin, cisplatin, and continuous infusion of 5‐fluorouracil (ECF)
Trial: 17244772
Drug: Maribavir 400
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir 400 mg
Trial: 15642685
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral vitamin K
Trial: 11997407
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects on HRV
Trial: 7712526
Drug: Creatine phosphate
RxNorm normalized name: Creatine phosphate
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine phosphate (CP) 18 g administered intravenously for 3 days
Trial: 2655543
Drug: Deflazacort (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort (18 + 18 mg)
Trial: 2655543
Drug: Prednisone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (15 + 15 mg)
Trial: 2655543
Drug: Betamethasone disodium
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone disodium phosphate (1.5 + 1.5 mg)
Trial: 31493952
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion (1 mg lidocaine/kg bolus followed by 180 mg lidocaine/hour for 7 days)
Trial: 7977713
Drug: ouabain (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ouabain (0.5 mg i.v. 42 and 18 h before study)
Trial: 2732784
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg twice a day)
Trial: 2732784
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) (160 mg trimethoprim and 800 mg sulfamethoxazole twice a day)
Trial: 27566723
Drug: Brexpiprazole (3.6mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole (3.6mg mean dose at last visit)
Trial: 23623280
Drug: CRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT plus cetuximab (400 mg/m² on day 1 followed by 250 mg/m² weekly)
Trial: 23623280
Drug: CRT only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT only (cisplatin 60 mg/m² on day 1 and capecitabine 625 mg/m² twice daily for four cycles)
Trial: 18802999
Drug: Pyridostigmine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (30 mg/8 hp. o)
Trial: 11912281
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg levonorgestrel (two doses of 0.375 mg each, 12 hours apart)
Trial: 20833596
Drug: Healthy Girls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy Girls Project intervention (4 weekly workshops with psychoeducational and behavioral components)
Trial: 18801028
Drug: N-acetylcysteine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (1200 mg daily for 4 months)
Trial: 9189040
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (i.v.Ig) 0.4 gm/kg daily for either 3 days (n = 23) or 5 days (n = 23)
Trial: 9189040
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (i.v.Ig)
Trial: 4022702
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (limited starvation, group B)
Trial: 24782199
Drug: Ondansetron 32
RxNorm normalized name: ondansetron 32 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 32 mg IV
Trial: 24782199
Drug: Ondansetron 16
RxNorm normalized name: ondansetron 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 16 mg IV
Trial: 20039806
Drug: DeltaNS1‐H1N1 A/New
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DeltaNS1‐H1N1 A/New Caledonia vaccine at 1 of 5 dose levels (6.4, 6.7, 7.0, 7.4, and 7.7 log(10) median tissue culture infective dose)
Trial: 20039806
Drug: DeltaNS1‐H1N1 A/New
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DeltaNS1‐H1N1 A/New Caledonia vaccine
Trial: 15916468
Drug: Betaine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine (6 g/d for 6 weeks)
Trial: 15916468
Drug: Phosphatidylcholine (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine (approximately 2.6 g/d of choline for 2 weeks)
Trial: 15916468
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.8 mg/d)
Trial: 10553160
Drug: Fludarabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine alone (25 mg/m²/day for 5 days)
Trial: 10553160
Drug: Fludarabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine and idarubicin (FLU-ID: fludarabine 25 mg/m² i.v. on days 1 to 3 and idarubicin 12 mg/m² i.v. on day 1)
Trial: 6368889
Drug: Rifampin-20 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin-20 (20 mg/kg/dose for four days)
Trial: 6368889
Drug: Rifampin-10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin-10 (10 mg/kg/dose for two to four days)
Trial: 29517695
Drug: Group S
RxNorm normalized name: Blood group substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S (n=27; dose reduced by 10% of each ED95)
Trial: 29517695
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (n=27; dose reduced by 20% of each ED95)
Trial: 26581819
Drug: Extended medication
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended medication (26 weeks of nicotine patch + nicotine gum)
Trial: 26581819
Drug: Extended medication
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended medication (8 weeks of nicotine patch + nicotine gum)
Trial: 26581819
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence counseling
Trial: 26581819
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication adherence counseling
Trial: 26581819
Drug: Automated (medication)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated (medication) adherence calls
Trial: 26581819
Drug: Electronic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic medication monitoring with feedback and counseling
Trial: 26581819
Drug: Electronic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic medication monitoring alone
Trial: 23787544
Drug: Paricalcitol 1
RxNorm normalized name: PARICALCITOL 1MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol 1 μg/day
Trial: 21558570
Drug: Quercetin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin supplementation (500 mg of quercetin-3-glucoside, consumed twice a day, totaling 1,000 mg/d)
Trial: 19433274
Drug: Clonidine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.05 mg, twice daily)
Trial: 19433274
Drug: Levetiracetam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (10 mg/kg/day, divided twice daily)
Trial: 27029450
Drug: Noophen 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noophen 500 mg/day
Trial: 24493231
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and metronidazole (AB) for 7 days
Trial: 24493231
Drug: Antibacterial photodynamic
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial photodynamic therapy (aPDT) with two episodes
Trial: 22331154
Drug: Conventional supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional supervised toothbrushing program (oral health education and dental plaque dying followed by toothbrushing with fluoride dentifrice four times per year)
Trial: 21384736
Drug: Local corticosteroid
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local corticosteroid injection plus splinting
Trial: 21178933
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg.kg-1 bm)
Trial: 9610454
Drug: Systemic diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic diclofenac sodium 50 mg given orally 1 hour before surgery
Trial: 7804666
Drug: Tiapride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapride (100 mg three times a day for at least one month)
Trial: 3243926
Drug: Intravenous ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ranitidine (50 mg over 5 minutes)
Trial: 11396641
Drug: Innovative techniques
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovative techniques and promising new drugs for the treatment of advanced epithelial ovarian cancer
Trial: 24829038
Drug: Specialized multidisciplinary
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized multidisciplinary tinnitus treatment based on cognitive behavioral therapy
Trial: 23242019
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg intravenously twice a day for fasting time, then 40 mg orally twice a day until discharge
Trial: 20152243
Drug: Ezetimibe/simvastatin (10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin (10/20 mg) plus niacin (to 2 g)
Trial: 20152243
Drug: Ezetimibe/simvastatin (10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin (10/20 mg)
Trial: 18817156
Drug: Combined sciatic-femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sciatic-femoral nerve block with ropivacaine 25 mL 0.75 mg
Trial: 2279254
Drug: Ibopamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (100 mg t.i.d.) for 3 weeks
Trial: 2279254
Drug: Ibopamine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (300 mg daily for 3 weeks)
Trial: 41542
Drug: Quinalbarbitone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinalbarbitone 200 mg
Trial: 41542
Drug: Quinalbarbitone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinalbarbitone 100 mg
Trial: 30646926
Drug: LOWFODMAP diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOWFODMAP diet (16.06 ± 1.79 g·d‐ 1)
Trial: 30646926
Drug: HIGHFODMAP diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGHFODMAP diet (38.65 ± 6.66 g·d‐ 1)
Trial: 27230850
Drug: LCZ696 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with mild renal impairment (N=8)
Trial: 27230850
Drug: LCZ696 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with moderate renal impairment (N=8)
Trial: 27230850
Drug: LCZ696 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with severe renal impairment (N=6)
Trial: 27230850
Drug: Healthy subjects
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects (CrCl >80 mL/min)
Trial: 21935705
Drug: Vorapaxar 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar 20 mg
Trial: 21935705
Drug: Vorapaxar 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar 40 mg
Trial: 21935705
Drug: Vorapaxar 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar 5 mg/day
Trial: 21935705
Drug: Vorapaxar 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar 1 mg/day
Trial: 21935705
Drug: Vorapaxar 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar 3 mg/day
Trial: 21122285
Drug: Therapy with
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy with ESWT (shock waves) and proprioceptive Multi Joint System, along with a specific nutritional supplement.
Trial: 21122285
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement in Group B2.
Trial: 21122285
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group B1 without nutritional supplement).
Trial: 11232674
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg once a day in the evening
Trial: 11232674
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg once a day in the morning
Trial: 9923581
Drug: Fluvoxamine 100
RxNorm normalized name: fluvoxamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 100 mg orally once daily for 5 days
Trial: 21410371
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine (200 mg/m² continuous IV infusion for 24 hours in cycle 1 and 1000 mg/m² by infusion for 3 hours twice daily in cycle 2)
Trial: 21410371
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (1000 mg/m² every 12 hours in cycle 1 and 2000 mg/m² twice daily in cycle 2)
Trial: 17166332
Drug: α1-adrenergic receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: α1-adrenergic receptor antagonists (α1-AR)
Trial: 17166332
Drug: Phosphodiesterase type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase type 5 inhibitors (PDE-5s)
Trial: 17166332
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of α1-AR antagonist and PDE-5
Trial: 15909750
Drug: Ethambutol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethambutol therapy
Trial: 9196083
Drug: rhuMAb-E25 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuMAb-E25 (2 mg/kg on Day 0 and 1 mg/kg on Days 7, 14, 28, 42, 56, and 70)
Trial: 8308939
Drug: Traditional alcoholism
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional alcoholism treatment for alcohol and cocaine abusers
Trial: 8308939
Drug: Traditional alcoholism
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional alcoholism treatment for alcohol-only patients
Trial: 3083718
Drug: 0.01 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg/kg nicardipine
Trial: 3083718
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg nicardipine
Trial: 17701271
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (10,000 lux, n = 10)
Trial: 15860501
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (ganirelix) administered daily from the 8th day of stimulation
Trial: 15860501
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (triptorelin) long protocol
Trial: 12595851
Drug: Dobutamine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (mean dose 4.1 +/- 1.4 microg/kg/min)
Trial: 12595851
Drug: Milrinone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (mean dose 0.39 +/- 1.0 microg/kg/min)
Trial: 10528419
Drug: Acarbose 300
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 300 mg per day for 24 weeks
Trial: 7084138
Drug: Oral information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral information about medications at initial interview
Trial: 3971235
Drug: Antiphlebitic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiphlebitic mixture of heparin‐hydrocortisone‐sodium bicarbonate
Trial: 24762026
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention including motivational aspects, cognitive aspects, and training in inhalation techniques
Trial: 26252875
Drug: Daclatasvir 60
RxNorm normalized name: daclatasvir 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily for 24 weeks
Trial: 26252875
Drug: Telaprevir 750
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir 750 mg three times daily for 12 weeks and peginterferon/ribavirin for 24 weeks
Trial: 20817281
Drug: Double-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose clopidogrel (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily)
Trial: 20817281
Drug: Standard-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose clopidogrel (300 mg on day 1 then 75 mg daily)
Trial: 20817281
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (300-325 mg daily)
Trial: 20817281
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (75-100 mg daily)
Trial: 18623043
Drug: Clindamycin 600
RxNorm normalized name: clindamycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 600 mg oral dose